| scholarly article | Q13442814 |
| P50 | author | Yaohe Wang | Q86626980 |
| P2093 | author name string | Nicholas R Lemoine | |
| Giulia Marelli | |||
| Anwen Howells | |||
| P2860 | cites work | Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant | Q45865272 |
| Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma | Q45878943 | ||
| Interview with Robert Coffin, inventor of T-VEC: the first oncolytic immunotherapy approved for the treatment of cancer | Q45882507 | ||
| Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells | Q46016751 | ||
| Retroviral replicating vectors in cancer | Q46655345 | ||
| Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness | Q47314747 | ||
| A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. | Q51756266 | ||
| Effects of glandular fever infection in acute leukaemia. | Q55499951 | ||
| Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner | Q64375110 | ||
| Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression | Q64379081 | ||
| Viruses with oncolytic properties and their adaptation to tumors | Q73949398 | ||
| Studies in Hodgkin's syndrome; the association of viral hepatitis and Hodgkin's disease; a preliminary report | Q80353957 | ||
| Rescue and propagation of fully retargeted oncolytic measles viruses | Q81348398 | ||
| Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer | Q81996205 | ||
| Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma | Q84906858 | ||
| Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles | Q21284969 | ||
| The human CD46 molecule is a receptor for measles virus (Edmonston strain) | Q24317745 | ||
| The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus | Q24533256 | ||
| Genetically engineered Newcastle disease virus for malignant melanoma therapy | Q24597831 | ||
| Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells | Q24602706 | ||
| Recombinant Newcastle disease virus as a vaccine vector for cancer therapy | Q24602728 | ||
| Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver | Q24633957 | ||
| p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines | Q24672443 | ||
| Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death | Q24674186 | ||
| Oncolytic virus therapy: A new era of cancer treatment at dawn | Q26739714 | ||
| Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity | Q26750568 | ||
| Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response. | Q27340224 | ||
| Leukaemia and neoplastic processes treated with Langat and Kyasanur Forest disease viruses: a clinical and laboratory study of 28 patients | Q27478205 | ||
| Viruses as nanomedicine for cancer | Q27690636 | ||
| The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery | Q32162676 | ||
| Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma | Q33441321 | ||
| Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1. | Q33490144 | ||
| Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins. | Q33621028 | ||
| Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity | Q33743847 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer | Q33932032 | ||
| Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy | Q33933665 | ||
| Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy | Q34028464 | ||
| Mechanism of adenovirus neutralization by Human alpha-defensins | Q40025786 | ||
| Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. | Q40036993 | ||
| Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy | Q40072336 | ||
| An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells | Q40125989 | ||
| A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus | Q40176322 | ||
| Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses | Q40183392 | ||
| Deletion of the intracellular domain of coxsackie and adenovirus receptor (CAR) enhances the expression of itself and boosts the efficiency of current adenovirus-mediated gene therapy in ovarian cancer cell lines in vitro | Q40197041 | ||
| MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2. | Q40267882 | ||
| A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus | Q40298957 | ||
| Adenovirus-induced extracellular signal-regulated kinase phosphorylation during the late phase of infection enhances viral protein levels and virus progeny | Q40322132 | ||
| High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus | Q40534840 | ||
| An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency | Q40546345 | ||
| Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy | Q40600575 | ||
| Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression | Q40626041 | ||
| Albumin-binding adenoviruses circumvent pre-existing neutralizing antibodies upon systemic delivery | Q40662862 | ||
| Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma | Q40702544 | ||
| Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. | Q40788613 | ||
| Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis | Q40906922 | ||
| Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. | Q40952636 | ||
| Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death | Q41744540 | ||
| Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes | Q42820783 | ||
| The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin | Q42947237 | ||
| Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus | Q42977068 | ||
| Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity | Q43601191 | ||
| In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents | Q43815948 | ||
| Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells | Q45110054 | ||
| Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity | Q45400531 | ||
| An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer | Q45407399 | ||
| China approves world's first oncolytic virus therapy for cancer treatment | Q45419325 | ||
| Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. | Q45526198 | ||
| Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier | Q45560504 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. | Q39455351 | ||
| Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. | Q39505379 | ||
| Adenovirus–Retrovirus Hybrid Vectors Achieve Highly Enhanced Tumor Transduction and Antitumor Efficacy In Vivo | Q39661200 | ||
| Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers | Q39752863 | ||
| Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours | Q39778777 | ||
| Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters | Q39881872 | ||
| Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo | Q39882822 | ||
| Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy | Q39974313 | ||
| A27L Protein Mediates Vaccinia Virus Interaction with Cell Surface Heparan Sulfate | Q34070135 | ||
| Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans | Q34212910 | ||
| Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer | Q34327051 | ||
| Suppression of IFN-Induced Transcription Underlies IFN Defects Generated by Activated Ras/MEK in Human Cancer Cells | Q34412329 | ||
| Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma | Q34478015 | ||
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. | Q34583808 | ||
| Chemical induction of unfolded protein response enhances cancer cell killing through lytic virus infection. | Q34594638 | ||
| The destructive effect of the virus of Russian Far East encephalitis on the transplantable mouse sarcoma 180. | Q34729202 | ||
| 2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells | Q34764233 | ||
| A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein | Q34808441 | ||
| Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter | Q35058583 | ||
| MicroRNA Regulation of Glycoprotein B5R in Oncolytic Vaccinia Virus Reduces Viral Pathogenicity Without Impairing Its Antitumor Efficacy | Q35086717 | ||
| Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma | Q35175013 | ||
| Vaccinia virus transcription | Q35199087 | ||
| Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer | Q35226511 | ||
| Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. | Q35285887 | ||
| Inhibitors of the interferon response enhance virus replication in vitro. | Q35414495 | ||
| HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy | Q35568782 | ||
| Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models | Q35587389 | ||
| CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy | Q35600445 | ||
| Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3. | Q35610920 | ||
| High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy | Q35686424 | ||
| Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. | Q35945465 | ||
| Critical Role of Autophagy in the Processing of Adenovirus Capsid-Incorporated Cancer-Specific Antigens | Q35993889 | ||
| Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus | Q36014057 | ||
| Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. | Q36071414 | ||
| Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect | Q36162804 | ||
| Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo. | Q36372763 | ||
| Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer | Q36757045 | ||
| JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase | Q36909702 | ||
| Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth | Q36951268 | ||
| Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy | Q37069810 | ||
| E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus | Q37110666 | ||
| Vaccinia virus, a promising new therapeutic agent for pancreatic cancer | Q37158473 | ||
| CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells | Q37209263 | ||
| Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma | Q37426827 | ||
| Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model | Q37455627 | ||
| Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. | Q37641495 | ||
| Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity | Q37651860 | ||
| 11R-P53 and GM-CSF Expressing Oncolytic Adenovirus Target Cancer Stem Cells with Enhanced Synergistic Activity | Q37667771 | ||
| Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model | Q37706248 | ||
| Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy | Q37709052 | ||
| The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model | Q38412419 | ||
| A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma | Q38425231 | ||
| Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. | Q38713629 | ||
| Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors | Q38714964 | ||
| Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy | Q38718549 | ||
| Enhanced Oncolytic Activities of the Telomerase-Specific Replication-Competent Adenovirus Expressing Short-Hairpin RNA against Dicer | Q38739646 | ||
| Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer | Q38755816 | ||
| Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity | Q38795358 | ||
| Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model. | Q38811582 | ||
| VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. | Q38849137 | ||
| Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma | Q38860227 | ||
| Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. | Q38879452 | ||
| Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. | Q38886874 | ||
| Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells | Q38918317 | ||
| An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites | Q38933648 | ||
| A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer | Q38938559 | ||
| MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. | Q38964020 | ||
| Viral persistence in colorectal cancer cells infected by Newcastle disease virus. | Q38989363 | ||
| Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. | Q39004582 | ||
| Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy | Q39016885 | ||
| Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. | Q39026166 | ||
| Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis | Q39213379 | ||
| Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. | Q39220397 | ||
| Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. | Q39442539 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 195 | |
| P577 | publication date | 2017-09-08 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer | |
| P478 | volume | 7 |
| Q64375454 | Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus |
| Q59360557 | Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model |
| Q114371080 | Cell surface heat shock protein-mediated entry of tumor cell-adapted rotavirus into U-937 cells |
| Q101139022 | Clinical CAR-T cell and Oncolytic Virotherapy for Cancer Treatment |
| Q92037568 | Convergence of Cell Pharmacology and Drug Delivery |
| Q90134243 | Development of oncolytic virotherapy: from genetic modification to combination therapy |
| Q50063970 | E pluribus unum: Combining Molecular Strategies to Defeat Head and Neck Cancer |
| Q56986466 | Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection |
| Q90191828 | Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives |
| Q104500570 | Mutant myogenin promoter-controlled oncolytic adenovirus selectively kills PAX3-FOXO1-positive rhabdomyosarcoma cells |
| Q64089752 | Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds |
| Q92010591 | Oncolytic Viruses: Priming Time for Cancer Immunotherapy |
| Q91596394 | Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival |
| Q98664265 | OvirusTdb: A database of oncolytic viruses for the advancement of therapeutics in cancer |
| Q91807970 | Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers |
| Q92223586 | Recent advances in oncolytic virus-based cancer therapy |
| Q64100856 | Recent advances in the development of gene delivery systems |
| Q64375906 | Recombinant Adenovirus KGHV500 and CIK Cells Codeliver Anti-p21-Ras scFv for the Treatment of Gastric Cancer with Wild-Type Ras Overexpression |
| Q92242774 | The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth |
| Q90326778 | Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors |
| Q90414077 | Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development |
| Q89704640 | oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity |
Search more.